



Regulated Information
4 August 2011

Interim Financial Report
First Half 2011

**Building
international
OTC brands**

Contents

Management statement.....	2
Business review of the first half of 2011	3
- Business performance at a glance.....	3
- Business highlights.....	3
- Main events (regulated information).....	7
- Outlook 2011.....	8
Consolidated income statement.....	9
Consolidated statement of comprehensive income.....	10
Consolidated balance sheet.....	11
Consolidated statement of changes in equity.....	12
Condensed consolidated cash flow statement.....	13
Selected notes.....	14
General information.....	14
Summary of significant accounting policies.....	14
Segment reporting.....	16
Main risks and uncertainties.....	17
Other notes.....	18
1. Income tax.....	18
2. Equity - treasury shares.....	18
3. Contingencies.....	18
4. Business combinations.....	18
5. Related parties.....	18
6. Significant events after balance sheet date.....	19
Review report of the statutory auditor.....	20

Management statement

The undersigned hereby declare that, to the best of their knowledge, the interim financial statements for the six-months period ended June 30, 2011, which have been prepared in accordance with the IAS 34 'Interim Financial Reporting' as adopted by the European Union, give a true and fair view of the equity, the financial situation and the results of Omega Pharma NV and the companies that are included in the consolidation scope.

The undersigned also declare that, to the best of their knowledge, the interim financial report provides a true and fair review of the important events that have occurred during the first six months of the financial year and of the other legally required information.

In the name and for the account of the Board of Directors

Marc Coucke, CEO

Barbara De Saedeleer, CFO

4 August 2011

Forward-looking statements

This report contains forward-looking information which is based on current internal estimates and expectations as well as market expectations. Forward-looking statements contain inherent risks and apply exclusively on the date they are made. The actual result may differ substantially from those included in the forward-looking statements. Differences between expectations and reality may vary significantly considering the reduced visibility which is inherent in the current political and economic environment, as well as its potential impact on generics, cost structures, taxes, consumer spending et cetera.

Business Review of the First Half of 2011

Key messages

- Turnover grew 7.3% in first half. Strong sales performance in France, the Nordics, Germany and the Netherlands, as well as for the Five Pillars. Turnover in Russia, Greece, Portugal and Spain remained under pressure.
- Operating cash flow ¹ up 7.6% versus first half 2010; margin stable at 14.2% of turnover
- Net recurring result ² flat at EUR 33.8 million
- Omega Pharma secured new credit facilities to fund operations and growth in the future

Business review

Key financial figures for the First Half 2011

(in EUR million)	1H2011	1H2010	Year on Year Evolution
Consolidated turnover	454.4	423.5	+7%
Gross Margin	242.2	225.9	+7%
Operating charges ³	-177.5	-165.8	+7%
EBITDA ¹	64.7	60.1	+8%
Depreciation and amortization, write-off of stock	-12.5	-9.2	
Net Recurring Result ²	33.8	33.7	0%
Net Recurring EPS ⁴	1.45	1.44	0%
Average number of shares ⁵	23,351,093	23,347,309	0%

Group turnover increased by 7%, of which 3% organic growth, driven by a strong performance in France, the Nordic countries, Germany and the Netherlands. Turnover in Russia, Greece, Portugal and Spain remained under pressure.

¹ Operating cash flow or EBITDA: operating result before non-recurring items, increased with depreciations and amortization

² Net result of the group before non-recurring items and adjusted for tax impact related to non-recurring items.

³ Services and other goods + Employee benefit expenses

⁴ Net recurring results (cf. note 2) divided by the average number of shares, as included in the table above

⁵ Weighted average of shares outstanding after deduction of treasury shares

The gross margin grew 7% and represents 53.3% of turnover - i.e. stable versus last year. Operating charges also grew in line with turnover.

The Operating cash flow (EBITDA) ¹ improved by 8% and represents 14.2% of turnover - i.e. flat versus the first half of 2010.

Depreciations and amortization increased from EUR 9.2 million to EUR 12.5 million, as a consequence of depreciations on enhanced R&D investments, recognized as intangible assets on the balance sheet, and of a provision for an amount of EUR 1.8 million for a doubtful debt in the Emerging Markets.

Non-recurring items amount to EUR 14.4 million and mainly refer to provisions for restructuring charges related to the intended closure of the manufacturing plant in Rotterdam and a provision for a legal dispute.

The Net Recurring Result ² amounts to EUR 33.8 million, corresponding with a net recurring EPS of EUR 1.45.

Working capital ⁶ was EUR 78.4 million and Net Financial Debt ⁷ on 30 June 2011 amounted to EUR 357.1 million compared to EUR 330.0 million on 31 December 2010.

New credit facilities to fund future growth

After balance sheet date, Omega Pharma has successfully refinanced its US private placement and its revolving credit facility, thus ensuring the funding of its operations and the growth of the group in the future. Omega Pharma has closed both a new US private placement of EUR 135 million and a new syndicated revolving credit facility of EUR 525 million.

The nominal principle amount of the new US private placement is EUR 135 million, which remains unchanged for the entire duration of the agreements, and is due in one single instalment end of July 2023. A Euro Fixed Rate of 5.1045% applies. Omega Pharma chose Pricoa Capital as sole investor for the transaction. The new US private placement is mainly used to refinance the EUR 130 million instalment of the previous private placement, which was due in July 2011.

The new revolving credit facility provides a total amount of EUR 525 million, with the option to increase this by an additional amount of EUR 150 million ('accordion'). There was a significant oversubscription from new and existing lenders, raising over EUR 600 million. The facility has therefore been increased from its launch size of EUR 450 million and lenders have been scaled back from their initial commitments. The new revolving credit facility is due in 2016, in one single instalment. Omega Pharma appointed Mizuho Corporate Bank, BNP Paribas Fortis, ING Belgium NV/SA and KBC Bank NV as Joint Coordinators to lead the transaction. Commerzbank Aktiengesellschaft together with Banque LBLux S.A., Credit Agricole Corporate and Investment Bank and Société Générale acted as Bookrunners and Mandated Lead Arrangers. Crédit Industriel et Commercial, London Branch, Raiffeisen Bank International AG and SEB were Lead Arrangers. Banco Bilbao Vizcaya Argentaria S.A. - Belgian Branch and J.P.Morgan Limited also participated in the transaction.

⁶ Inventories plus Trade receivables minus Trade payables

⁷ Current and non-current financial liabilities, excluding current and non-current derivative financial instruments, minus cash and cash equivalents

Barbara De Saedeleer, Chief Finance Officer (CFO) Omega Pharma, comments: “We are very pleased with the result of these successful transactions, refinancing our core credit facilities with existing and several new lenders, demonstrating the confidence that the loan market has in Omega Pharma.”

Overview of current and future credit facilities	Situation end 2010	Situation end 2011	Maturity
USPP 2004	EUR 187 million	EUR 57 million	2014, 2016
USPP 2011		EUR 135 million	2023
Syndicated credit facility 2006	EUR 450 million	-	-
Syndicated credit facility 2011	-	EUR 525 million (+ EUR 150 million 'accordion')	2016

Segment performance

(in EUR million)	Turnover		Operating Cash Flow (EBITDA) ¹			
	1H2011	YoY evolution	1H2011	Margin (% of sales)	1H2010	YoY evolution
Western Europe	184.8	+5.2%	36.9	20.0%	35.4	+4%
Belgium	134.3	+7.8%	21.4	15.9%	18.2	+18%
Emerging Markets	48.5	+4.5%	5.4	11.1%	4.3	+26%
France	86.9	+13.2%	11.6	13.3%	9.1	+27%
Corporate			-10.6		-6.9	+54%
Total Group	454.4	+7.3%	64.7	14.2%	60.1	+8%

Western Europe. Both in the first and the second quarter, sales in this segment were negatively impacted by the financial-economic situation in Greece, Portugal and Spain. This was only partly offset by the strong sales performance in the main other markets of this region. Lower sales in the aforementioned markets led to suboptimal cost coverage in the corresponding organizations, which impacted profitability. In order to address this issue, Omega Pharma reviewed the organizational structure in selected countries. The UK also posted a poor performance in terms of profitability, while the Netherlands and the Nordics performed well.

Belgium. The Belgian organization continued its strong performance in the first six months of 2011. However, the impressive +12.7% sales growth of the first quarter –with equal growth rates for OTC products and generics– could not be entirely extended into the second quarter.

Emerging Markets. The situation in this reporting segment is mainly defined by the weak performance in Russia, as already mentioned in the trading update on the first quarter. Fluctuating influenza incidence had a negative impact on cough & cold products in the fourth quarter 2010 and the first quarter 2011. Omega Pharma decided to reinvigorate the Russian organization under the leadership of a new Country Manager, who became operational early July 2011. The organization in Ukraine had a strong quarter and also the other CEE countries managed to strengthen their local positions based on the required investments.

France. The French organization successfully extended the momentum since its turnaround in the third quarter of 2010. The double digit sales growth in both the first and the second quarter of 2011 confirms that the French team has embarked a structural improvement process.

Brand performance

The turnover of the products in the five strategic pillars has grown 13% and represents 54.2% of total consolidated turnover in the first half of 2011.

Turnover per pillar

In EUR thousand	1H2011	1H2010	Evolution
Derma	102 988	97 978	+5%
Classics	53 684	45 062	+19%
Parasites	40 795	39 609	+3%
Cough & Cold (& Allergy)	33 350	18 871	+77%
Multi-locals	15 519	16 307	-5%
Subtotal for the five pillars	246 337	217 826	+13%
<i>As % of total sales</i>	<i>54.2%</i>	<i>51.4%</i>	

R&D and innovation of Omega Pharma are concentrated around these five pillars, and the corresponding brands are rolled out country by country.

Approximately half of the 13% year-on-year growth is organic; the remainder refers to the inclusion of Physiomer (Laboratoire de la Mer), Duo LP Pro (Terra Santé) and a number of other, smaller acquisitions in the Group's consolidation circle.

Omega Pharma's ten biggest brand, according to turnover in the first half of 2011, are (alphabetically ranked): ACO, Clément-Thékan, Davitamon, Jungle Formula, Paranix, Phytosun, Predictor, Silence, XLS and Wartner. Their joint turnover amounted to EUR 121.2 million in the first half of 2011 - i.e. 14.5% up against the same period last year.

This Business Review is edited by the Board of Directors of Omega Pharma.

Main events (regulated information)

Preceding the publication of this 2011 Interim Report, Omega Pharma has communicated the following regulated information in 2011.

- On January 13, Omega Pharma announced the acquisition of Duo LP Pro and of five OTC brands from Goldshield. Duo LP Pro is an anti-headlice product which generated almost EUR 6 million in turnover in 2010 and which strengthens the product portfolio of Omega Pharma France. The acquired Goldshield brands mainly refer to slimming products which generated approximately EUR 3 million in turnover in 2010 and which provide a solid basis for launching the XLS Medical project in the UK and Ireland. The combined purchase price for both acquisitions was EUR 14 million.
- On January 20, Omega Pharma published a Trading Update (including sales figures) on the fourth quarter and the full year 2010.
- On February 2, Omega Pharma announced the departure of Georges De Vos, COO.
- At the occasion of the publication of the Full Year 2010 Results, on 28 February 2011, Omega Pharma announced the promotion of Chris Staueble - until then Group Marketing Manager - to Vice President, Head of Marketing and Sales, and member of the Executive Committee. Omega Pharma also guided for a 2011 turnover of EUR 927 million and stable margins.
- On April 14, Omega Pharma published a Trading Update on the first quarter 2011, including turnover figures for the quarter (7.8% overall growth, 3.5% internal growth) and a reiteration of the 2011 prognosis “taking into account improved results in the second half of 2011 in the Emerging Markets and Southern Europe“.
- In April 2011, Omega Pharma published its 2010 annual report and issued the convocations, agendas, proxy forms and a related board report for the annual and extraordinary shareholder meetings to be held in May. At the annual shareholder meeting held on 2 May, Marc Coucke, CEO Omega Pharma, also referred to the main risks and uncertainties, as published in the 2010 annual report. All motions were approved at the annual shareholder meeting. Consequently, Omega Pharma announced on 6 May that the dividend over the 2010 period became payable. As the required quorum for the extraordinary shareholder meeting was not reached on May 2, a new meeting was convened and held on 17 June, which approved all motions.
- On May 27, Omega Pharma issued a press release in response to an article in a Belgian newspaper on the alleged delisting plans of Omega Pharma. On July 11, Omega Pharma issued another press release in response to further articles in the Belgium media on this subject,

reconfirming that the Company analyzes several strategic scenarios on a regular basis and that a delisting (with a working assumption of EUR 37 per share for the bid price) is one of those potential scenarios.

- On June 14, Omega Pharma announced its intention to close its factory in Rotterdam (the Netherlands) and relocate the manufacturing operations to its plant in Feldkirchen (Austria). This intention would involve 64 job losses in Rotterdam.

Outlook 2011*

Omega Pharma provides an outlook for a turnover of EUR 927 million in 2011, with approximately stable margins, assuming improved results in the second half of 2011 in the Emerging Markets and Southern Europe.

* *Cfr. Forward-looking statements, page 2 of this document*

Consolidated income statement

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	January-June 2011	January-June 2010
Operating income	459 473	427 017
Turnover	454 454	423 474
Other operating income	5 019	3 543
Operating expenses	-421 669	-382 372
Trade goods	-212 260	-197 597
<i>Trade goods purchased</i>	-221 919	-210 128
<i>Changes in inventories of raw materials, components, work in progress and finished goods.</i>	9 659	12 531
Services and other goods	-122 568	-117 240
Employee benefit expenses	-56 079	-48 628
Depreciations and amortization	-11 459	-8 726
Changes in write-offs stocks & trade receivables	-1 080	-454
Changes in provisions for liabilities	-633	-437
Other operating expenses	-17 590	-9 290
<i>Of which other</i>	-3 210	-2 977
<i>Of which restructuring charges</i>	-14 380	-6 313
Operating result	37 804	44 645
Financial income	586	614
Financial expense	-11 507	-12 586
Financial result	-10 921	-11 972
Result income tax	26 883	32 673
Income tax	-4 891	-4 456
Result after income tax	21 992	28 217
Of which attributable to the shareholders of the parent company	22 203	28 343
Of which attributable to non-controlling interests	-211	-126
<i>Total number of shares outstanding on June 30</i>	<i>24 232 318</i>	<i>24 227 303</i>
<i>Of which treasury shares)</i>	<i>879 994</i>	<i>879 994</i>
<i>Weighted average after deduction of treasury shares</i>	<i>23 352 324</i>	<i>23 347 309</i>
<i>Earnings per share (in EUR)</i>	<i>0.96</i>	<i>1.21</i>
<i>Earnings per share excluding non-recurring items ⁽¹⁾ (in EUR)</i>	<i>1.45</i>	<i>1.44</i>
<i>Diluted earnings per share ⁽²⁾ (in EUR)</i>	<i>0.96</i>	<i>1.20</i>

(1) Based on net result for the Group, minus restructuring charges and tax effect of restructuring charges

(2) Taking the dilutive impact of outstanding warrants which are "in the money" into account

Consolidated statement of comprehensive income

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	Fair value and other reserves	Cumulative translation adjustments	Retained earnings	Attributable to the share- holders of the parent company	Attributable to non- controlling Interests	Total equity
Fair value gains/(losses) on cash flow hedges	1 742			1 742		1 742
Fair value gains/(losses) on cash flow hedges - Tax effect	-592			-592		-592
Currency translation adjustments		4 391		4 391		4 391
Profit for the period			28 343	28 343	-126	28 217
Total recognized income for the period ended 30 June 2010	1 150	4 391	28 343	33 884	-126	33 758

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	Fair value and other reserves	Cumulative translation adjustments	Retained earnings	Attributable to the share- holders of the parent company	Attributable to non- controlling Interests	Total equity
Fair value gains/(losses) on cash flow hedges	1 520			1 520		1 520
Fair value gains/(losses) on cash flow hedges - Tax effect	-517			-517		-517
Currency translation adjustments		-1 791		-1 791		-1 791
Profit for the period			22 203	22 203	-211	21 992
Total recognized income for the period ended 30 June 2011	1 003	-1 791	22 203	21 415	-211	21 204

Consolidated balance sheet

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	30 June 2011	31 December 2010
Non-current assets	1 122 129	1 090 896
Intangible assets	1 025 287	997 948
Property, plant and equipment	47 278	46 123
Financial assets	1 940	1 940
Deferred income tax assets	38 353	36 164
Other non-current assets	9 271	8 721
Current assets	368 305	350 585
Inventories	131 395	121 311
Trade receivables	156 334	141 721
Other current assets	41 971	53 730
<i>Of which income tax assets</i>	12 623	8 249
Cash and cash equivalents	38 605	33 823
Assets held for sale	1 575	1 949
TOTAL ASSETS	1 492 009	1 443 430
EQUITY	716 205	718 274
Share capital and share premium	366 971	366 941
Retained earnings	374 868	376 016
Treasury shares	-24 144	-24 144
Fair value and other reserves	1 743	739
Cumulative translation adjustments	-3 240	-1 448
Equity attributable to the shareholders of the parent company	716 198	718 104
Equity attributable to non-controlling interests	7	170
LIABILITIES	775 804	725 156
Non-current liabilities	172 899	172 317
Provisions	7 526	4 643
Pension obligations	5 377	4 726
Deferred income tax liabilities	83 632	85 910
Borrowings (non-current financial liabilities)	67 545	70 693
<i>Of which fair value of the hedged part of the USPP</i>	-8 431	-4 477
Other non-current liabilities	1 359	738
Derivative financial instruments	7 460	5 607
Current liabilities	602 905	552 839
Borrowings (current financial liabilities)	300 450	278 791
<i>Of which fair value of the hedged part of the USPP</i>	-19 272	-9 859
Trade payables	209 372	200 977
Income tax liabilities	40 642	26 386
Taxes, remuneration and social security	15 660	14 998
Other current payables	17 314	22 231
Derivative financial instruments	19 467	9 456
TOTAL EQUITY AND LIABILITIES	1 492 009	1 443 430

Consolidated statement of changes in equity

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	Number of shares	Share capital and share premium	Treasury shares	Fair value & other reserves	Cumulative translation adjustments	Retained earnings	Attributable to Shareholders of parent company	Attributable to non-controlling interests	Total equity
Amount 31 December 2009	23 347 309	366 841	-24 144	-1 284	-6 659	325 219	659 973	545	660 518
Total comprehensive income for the period ended 30 June 2010		0	0	1 150	4 391	28 343	33 884	-126	33 758
Capital increases		0					0		0
Employee share options scheme				8			8		8
Dividend on treasury shares						704	704		704
Dividend						-19 382	-19 382		-19 382
Non-controlling interests							0	28	28
Amount 30 June 2010	23 347 309	366 841	-24 144	-126	-2 268	334 884	675 187	447	675 634
Amount 31 December 2010	23 351 086	366 941	-24 144	739	-1 448	376 016	718 104	170	718 274
Total comprehensive income for the period ended 30 June 2011		0	0	1 003	-1 791	22 203	21 415	-211	21 204
Capital increases	1 238	30					30		30
Employee share options scheme									
Dividend on treasury shares						880	880		880
Dividend						-24 231	-24 231		-24 231
Non-controlling interests								48	48
Amount 30 June 2011	23 352 324	366 971	-24 144	1 742	-3 239	374 868	716 198	7	716 205

Condensed consolidated cash flow statement

<i>Figures submitted to a limited review, IFRS (in EUR thousand)</i>	January-June 2011	January-June 2010
Profit before income tax	26 883	32 673
Taxes paid	-5 093	-2 378
Adjustments for operational non-cash items	17 453	8 305
Adjustments for interests and financial non-cash items	9 833	9 501
Gross cash flow from operating activities	49 077	48 101
Changes in working capital	-19 887	-15 802
Total cash flow from operating activities	29 190	32 299
Capital expenditure	-21 022	-17 385
Disposals of investment goods	19 862	121
Cash and cash equivalents from acquisitions	461	0
Investments in existing shareholdings (post payments) and in new holdings	-21 938	-4 034
Dividends received	0	0
Total cash flow from investing activities	-22 636	-21 298
Proceeds from the issue of share capital	30	0
Purchases of own shares	0	0
Dividend distribution	-23 195	-15 969
Change in debts	30 924	20 490
Interests received (paid)	-9 114	-8 007
Total cash flow from financing activities	-1 356	-3 486
Net increase/decrease of cash flows for the period	5 198	7 515
Cash and cash equivalents - start of the period	33 823	25 229
Gains or losses on currency exchange on liquid assets	-417	750
Cash and cash equivalents - end of the period	38 605	33 494
Total net cash flow of the period	5 198	7 515

Selected notes

General information

Omega Pharma is a pure play in OTC with focus on prescription-free medicines and personal care products. The company's brands are clustered around five pillars: Derma (both cosmetics and medicated skin care products), Cough & Cold (including Allergy), Parasites, Classics (Omega Pharma heritage brands) and Multi-locals.

Since its creation in 1987, Omega Pharma has expanded from its Belgian home base into 35 countries across Europe and beyond, and is now positioned in the Top Fifteen ranking of the global OTC market.

The Company's shares are listed on the regulated market NYSE Euronext Brussels.

The condensed consolidated interim financial statements for the six months' period ended 30 June 2011 have been prepared in accordance with IAS 34 "Interim Financial Reporting" as adopted by the European Union. This document should be read together with the consolidated annual accounts for the period 2010 (including the significant accounting policies) as published in the 2010 annual report, which is available on www.omega-pharma.be (Investor Relations section).

These condensed consolidated interim financial statements have been approved for publication by the Board of Directors of August 3, 2011. They have been submitted to a limited review by the Statutory Auditor (cf. page 20).

Summary of significant accounting policies

The principal accounting policies applied in preparation of these consolidated interim financial report are identical to those applied in preparation of the consolidated financial statements for the year ended on December 31, 2010.

A summary of the principal accounting policies can be found on in Note 2 to the consolidated financial statements as included in the 2010 annual report, which can be consulted and downloaded via the following web link: <http://omega-pharma.be.res7.mijnpreview.com/uploads/700/Omega%20Pharma%202010%20annual%20report%20compl.pdf>.

The following new standards and amendments to standards are mandatory for the financial year beginning 1 January 2011 and have been adopted by the Group, when relevant:

- Amendment to IAS 32 'Classification of rights issues' requiring rights issues within the scope of the amendment to be classified as equity. The amendments are effective for annual periods beginning on or after 1 February 2010.
- Amendments to IFRS 1 providing a limited exemption from comparative IFRS 7 disclosures for first-time adopters, effective as of 1 July 2010.
- IAS 24 Revised 'Related-party transactions', effective for annual periods beginning on or after 1 January 2011. The revised standard amends the definition of a related party and modifies certain related party disclosure requirements for government-related entities.
- 'Improvements to IFRSs' (2010) amending IAS 1, IAS 27, IAS 34, IFRS 1, IFRS 3, IFRS 7 and IFRIC 13. These improvements are effective 1 January 2011.
- IFRIC 19 'Extinguishing financial liabilities with equity Instruments', effective for periods beginning on or after 1 July 2010. IFRIC 19 clarifies the accounting when a debtor and creditor might renegotiate the terms of a financial liability with the result that the debtor extinguishes the liability fully or partially by issuing equity instruments to the creditor.
- Amendments to IFRIC 14 'Pre-payments of a minimum funding requirement', effective for annual periods beginning on or after 1 January 2011. The amendment removes an unintended consequence of IFRIC 14 arising from the treatment of prepayments of future contributions in some circumstances when there is a minimum funding requirement.

The following new standards, amendments to standards and interpretations have been issued, but are not mandatory for the first time for the financial year beginning 1 January 2011 and have not been endorsed by the European Union and have not been early adopted:

- Amendments to IFRS 1 'First-time adoption of IFRSs' related to severe hyperinflation and the removal of fixed dates for first-time adopters. These amendments are effective on or after 1 July 2011.
- Amendments to IFRS 7 'Financial instruments: disclosures' requiring enhanced disclosures of transferred financial assets. These revisions are effective at the earliest for annual periods beginning on or after 1 July 2011.
- Amendments to IAS 1 'Presentation of financial statements', effective on or after 1 July 2012. The amendment changes the disclosure of items presented in other comprehensive income (OCI) in the statement of comprehensive income.
- Amendments to IAS 12 'Deferred taxes', effective on or after 1 January 2012. The amendments provide a practical approach for measuring deferred tax liabilities and deferred tax assets when investment property is measured using the fair value model.
- IFRS 9 'Financial instruments', effective for periods beginning on or after 1 January 2013. The standard addresses the classification, measurement and derecognition of financial assets and financial liabilities.
- IFRS 10 'Consolidated financial statements', effective for annual periods beginning on or after 1 January 2013. The new standard builds on existing principles by identifying the concept of control as the determining factor in whether an entity should be included within the consolidated financial statements.

- IFRS 11 ‘Joint arrangements’, effective for annual periods beginning on or after 1 January 2013. The new standard focuses on the rights and obligations rather than the legal form. Proportional consolidation is no longer allowed.
- IFRS 12 ‘Disclosure of interests in other entities’, effective for annual periods beginning on or after 1 January 2013. This a new standard on disclosure requirements for all forms of interests in other entities.
- IFRS 13 ‘Fair value measurement’, effective for annual periods beginning on or after 1 January 2013. The new standard explains how to measure fair value for financial reporting.
- IAS 19 Revised ‘Employee benefits’, effective for annual periods beginning on or after 1 January 2013. Through these amendments significant changes are made to the recognition and measurement of defined benefit pension expense and termination benefits, and to the disclosures for all employee benefits.
- IAS 27 Revised ‘Separate financial statements’, effective for annual periods beginning on or after 1 January 2013. The revised standard includes the provisions on separate financial statements that are left after the control provisions of IAS 27 have been included in the new IFRS 10.
- IAS 28 Revised ‘Investments in associates and joint ventures’, effective for annual periods beginning on or after 1 January 2013. The revised standard now includes the requirements for joint ventures, as well as associates, to be equity accounted following the issue of IFRS 11.

Segment reporting

During the first half of 2011, the segment reporting has not changed compared to the first six months ending 30 June 2010.

The segment results for the period ending June 30, 2010 were as follows:

<i>Figures submitted to a limited review, IFRS in thousand euro</i>	Total turnover	Inter-segment turnover	Net turnover	EBITDA*	Operating result of the segment
Western Europe	189 428	-13 716	175 712	35 449	30 287
Belgium	133 122	-8 482	124 640	18 219	16 437
Emerging Markets	47 346	-934	46 412	4 294	1 201
France	78 198	-1 488	76 710	9 142	5 422
Not allocated	-	-	-	-6 966	-8 702
Total Omega Pharma	448 094	-24 620	423 474	60 138	44 645

Reconciliation with the result from ordinary activities before income tax

Depreciations and amortization	-	-	-9 180
Non-recurring items (restructuring charges)			- 6 313
Financial result			- 11 972
Result before income tax			32 673

(*) Operating result before non-recurring items, increased with depreciations and amortization.

The segment results for the period ending June 30, 2011 are as follows:

<i>Figures submitted to a limited review, IFRS in thousand euro</i>	Total turnover	Inter-segment turnover	Net turnover	EBITDA*	Operating result of the segment
Western Europe	195 747	-10 944	184 803	36 893	20 533
Belgium	144 153	-9 850	134 303	21 386	19 901
Emerging Markets	49 363	-870	48 493	5 376	957
France	87 800	-945	86 855	11 628	8 919
Not allocated	-	-	-	-10 559	-12 506
Total Omega Pharma	477 063	-22 609	454 454	64 724	37 804

Reconciliation with the result from ordinary activities before income tax

Depreciations and amortization	-	-12 540			
Non-recurring items (restructuring charges)				-14 380	-
Financial result				-10 921	
Result before income tax				26 883	

(*) Operating result before non-recurring items, increased with depreciations and amortization.

Main risks and uncertainties

The Board of Directors of Omega Pharma considers that the main risks and uncertainties which could have a material impact on the Group's performance in the remaining part of 2011 are identified in Note 3 to the consolidated financial statements, as published in the 2010 annual report (<http://omega-pharma.be.res7.mijnpreview.com/uploads/700/Omega%20Pharma%202010%20annual%20report%20compil.pdf>), with the following updates and specifications:

- **Business cycle risk.** In addition to the information included in the 2010 annual report, Omega Pharma considers that the current state debt crisis in Greece, Portugal and Spain may have a further impact on overall consumer confidence and hence also on OTC consumption. The Company cannot exclude that such an impact may occur in additional geographic markets (e.g. Italy,...) in the further course of 2011.
- **US private placement hedges and fair value risk.** In July 2011, Omega Pharma has secured new credit lines to fund operations and growth in the future. As a consequence, the data included in Note 6.12 of the 2010 annual report has become outdated. Omega Pharma considers that the related risks have not increased as a result of the new credit lines.
- **Investment risk.** The coming years, Omega Pharma needs to make considerable investments in its brands and country organizations in order to build a long-term brand portfolio. Because it is difficult to predict the timing for making these investments profitable, this may cause a strong volatility of short-term results.

Other notes

1. Income tax

The amount of the income taxes is a management estimate and is based on an expected average effective tax rate of 18.2% for the entire accounting period 2011.

2. Equity - treasury shares

In accordance with article 620 of the Belgian Company Code, the Extraordinary General Meeting of Shareholders of 9 June 2009 granted authorization to the Board of Directors to buy back Company shares. This authorization has been renewed by the Extraordinary General Meeting of Shareholders of 17 June 2011.

During the first six months of 2011 no use has been made of this authorization. On 30 June 2011, Omega Pharma held 879,994 treasury shares which were previously purchase, and which then represented a total amount of EUR 24.1 million.

3. Contingencies

During the first six months of 2011 no material changes occurred to the situation as described in Note 7.1 of the 2010 annual report, with the exception of a legal claim related to a distribution agreement for a.o. Prevnar. This claim refers to a total amount of EUR 8.4 million and a provision has been created for slightly over half of that amount.

4. Business combinations

During the first six months of 2011, Omega Pharma completed the acquisition of Duo LP Pro. Duo LP Pro is an anti-head lice product which generated almost EUR 6 million turnover in 2011 and which strengthens the product portfolio of Omega Pharma France. Because the 2010 annual turnover of this acquisition represented no more than approximately one per cent of the consolidated 2010 turnover of the Group, they are deemed not sufficiently material for providing further details. The purchase price allocation has been temporary defined on June 30, 2011.

5. Related parties

Related parties refer to the members of the Executive Committee and the non-executive members of the Board of Directors.

The remuneration of the members of the members of the Executive Committee and the non-executive members of the Board of Directors is determined on an annual basis, for which reason no further details are included in this interim financial report.

6. Significant events after balance sheet date

- On July 8, Omega Pharma informed that 1,238 new securities conferring voting rights have been issued as a consequence of the exercise of warrants. As a result, the number of voting rights is now 24,232,318 and the share capital amounts to EUR 16,468,069.60.
- On July 11, Omega Pharma issued a press release in response to articles in the Belgium media on the alleged delisting plans of Omega Pharma, reconfirming that the Company analyzes several strategic scenarios on a regular basis and that a delisting which could be organized together with its controlling shareholder, Couckinvest NV (and with a working assumption of EUR 37 per share for the bid price) is one of those potential scenarios.
- In today's press release (4 August 2011) announcing the publication of Omega Pharma's 2011 interim results, the Company also stated that it has secured new credit facilities to fund operations and growth in the future. Omega Pharma has closed both a new US private placement (EUR 135 million) and a new syndicated credit facility (EUR 525 million).

Review report of the statutory auditor

Report of the statutory auditor on the review of the condensed consolidated interim financial statements of Omega Pharma NV for the half year ended 30 June 2011

We have reviewed the accompanying condensed consolidated interim financial statements of Omega Pharma NV (“the Company”) and its subsidiaries (jointly “the Group”), as of and for the six-month period ended 30 June 2011, consisting of the interim consolidated balance sheet, the related consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity and condensed consolidated cash flow statement for the six month period then ended, as well as the selected explanatory notes, with a balance sheet total of K EUR 1.492.009 and a profit for the period, part of the Group, of KEUR 22.203. The board of directors is responsible for the preparation and fair presentation of these consolidated condensed interim financial statements in accordance with IAS 34 as adopted by the European Union. Our responsibility is to express a conclusion on these consolidated interim financial statements based on our review.

We conducted our review in accordance with International Standard on Review Engagements 2410, “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the consolidated condensed interim financial statements referred to above are not prepared, in all material respects, in accordance with IAS 34 as adopted by the European Union.

Ghent, 04 August 2011

PwC Bedrijfsrevisoren
Represented by

Peter Opsomer
Partner